AnaptysBio(ANAB) - 2025 Q3 - Quarterly Results

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update SAN DIEGO, Nov. 4, 2025 — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. "Our intent to separate our wholly owned biopharma programs from our royalty assets provides investors with the opportunity to realize and enhance the potentia ...